We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
- Authors
Hutchings, M.; Dickinson, M.; Carlo‐Stella, C.; Morschhauser, F.; Bosch, F.; Gritti, G.; Townsend, W.; Bartlett, N. L.; Cartron, G.; Ghesquieres, H.; Houot, R.; Walter, H.; Offner, F.; Christiansen, A.; Dimier, N.; Jamois, C.; Harrop, E.; Herter, S.; Hölzlwimmer, G.; Keelara, A.
- Abstract
B Introduction: b The antibody-like fusion protein RO7227166 simultaneously targets CD19 on B-cells and 4-1BB (CD137) on T cells. RO7227166 doses ranging from 360 ug up to 75 mg were assessed and the maximum tolerated dose was not reached. COMBINING CD19-4-1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.
- Subjects
NON-Hodgkin's lymphoma; DIFFUSE large B-cell lymphomas
- Publication
Hematological Oncology, 2023, Vol 41, p136
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_91